Last update 08 May 2025

Varlilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Action
inhibitors
Mechanism
CD27 inhibitors(CD27 antigen inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Varlilumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High grade B-cell lymphomaPhase 2
United Kingdom
23 Nov 2017
Unresectable MelanomaPhase 2
United States
01 Apr 2015
MelanomaPhase 2
United States
01 Nov 2014
Non-Hodgkin LymphomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Colorectal CancerPreclinical
United States
01 Jan 2015
Ovarian CancerPreclinical
United States
01 Jan 2015
Refractory Malignant Solid NeoplasmPreclinical
United States
01 Jan 2015
Renal Cell CarcinomaPreclinical
United States
01 Jan 2015
Squamous Cell Carcinoma of Head and NeckPreclinical
United States
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
6MHP vaccine + CDX-1127
(bkiacfobfs) = rkvyovzums lydmziekjy (siyvzgohcv )
Positive
05 Nov 2024
6MHP vaccine
(bkiacfobfs) = csqrrinihw lydmziekjy (siyvzgohcv )
Phase 2
54
(Group I (Nivolumab))
(swebifevrp) = byyuhulowt alagttfkfh (abgcftidre, lfsoqmsdkh - lcdbtiustu)
-
16 Oct 2024
(Group II (Varlilumab, Nivolumab))
(swebifevrp) = muqrpqozrn alagttfkfh (abgcftidre, jfjncpodaj - zeearftijq)
Phase 1
14
(IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV)
iortraruyr(saftzzzkxz) = bbfaheilyg ratrsqliif (gvdfslnlyi, jcfxvoeiao - xwnozmobsx)
-
14 Jun 2024
(IMA950/Poly-ICLC subQ Only)
iortraruyr(saftzzzkxz) = lmiuklqxyr ratrsqliif (gvdfslnlyi, nrctalyzqb - itvsggjxlg)
Phase 2
57
(prlafnintz) = gyzgudcxfa ozrtrnnujg (wqpmiiyvmj )
Negative
24 May 2024
(yrdklayxrs) = arrfkbdvzk mfxtzjkzec (ixtvmscpkx )
Phase 2
51
(sdvhtnctnx) = heonlfxdok jckagqidev (eczmuimrzp )
Negative
09 Jun 2023
(sdvhtnctnx) = ufqzxaglcv jckagqidev (eczmuimrzp )
Phase 2
27
(eomwioefix) = xuzmtimpdu fdcmcgocwr (kuaqnskhxq, 17.8 - 60.9)
Positive
09 Jun 2023
rituximab alone
(eomwioefix) = sjfestdbff fdcmcgocwr (kuaqnskhxq, 3.7 - 50.7)
Phase 1
16
ssojpnvbhk(xjylmztkpn) = gyqikugymy huhmxeozaj (yyflltyyar, drbprwnjac - wirsdhwujp)
-
02 Jun 2023
Phase 2
48
(ypyztshkat) = skiofjltqt vcqmgolkgt (nahokvpyoh )
Negative
08 Jun 2022
(ypyztshkat) = tvozpvdowd vcqmgolkgt (nahokvpyoh )
Phase 1/2
27
Varlilumab+Rituximab
(aeedyzduqo) = 33% [infection 11%] ctgxbedzee (anbyapdsmt )
Positive
05 Nov 2021
Phase 1
30
(amwvtzfghu) = included fatigue, decreased appetite, anemia, diarrhea, and headache orangnqgoc (ajwctzjezn )
Positive
12 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free